We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB

By LabMedica International staff writers
Posted on 06 Feb 2020
Print article
Illustration
Illustration
GeneMatrix (Seoul, South Korea) promoted its main NeoPlex family of sex and respiratory infection testing products, at MEDLAB Middle East, which took place from 3-6 February 2020 at the Dubai World Trade Centre. MEDLAB Middle East, the Middle East & North Africa (MENA) region’s largest medical laboratory exhibition and congress, drew over 25,800 medical laboratory industry professionals and 600 exhibitors from 35 countries.

GeneMatrix focuses on leading the personalized medicine business through the development of competitive platforms and molecular diagnosis products. GeneMatrix’s proprietary RFMP platform technology can derive values from the genetic information of living creatures. The RFMP technology embodies unparalleled specifications for precision, sensitivity, digitalized quantitative analysis, multi-biomarker’s batch analysis and large quantity sample processing. The elements of biotechnology, nanotechnology and IT technology are organically fused in RFMP technology, and it is now being widely used. Its utilization will be extended to early diagnosis, prognosis determination, selection of therapeutic agent, treatment reaction monitoring for chronic intractable diseases including infectious, metabolic, neoplastic and genetic diseases.

At MEDLAB Middle East 2020, promoted sex and respiratory infection testing products of its main pipeline, NeoPlex, which are based om the company's original C-Tag technology. GeneMatrix offers multiple products in its respiratory testing line. In the respiratory virus panel line, it has developed NeoPlex RV-Panel A and NeoPlex RV-Panel B, while in the bacterial panel line it has developed NeoPlex RB-8.

GeneMatrix’s NeoPlex RV-Panel A is capable of collectively diagnosing 10 major respiratory viral pathogens, including influenza A/B, respiratory syncytial virus A/B, parainfluenza 1/2/3, and adenovirus, in a single test. Its NeoPlex RV-Panel B can simultaneously diagnose nine respiratory viruses, including coronavirus, enterovirus, and rhinovirus. GeneMatrix has completed the clinical trials of NeoPlex RV-Panel B which is ready for early market release.

Related Links:
GeneMatrix


Print article

Channels

Molecular Diagnostics

view channel
Image: New research suggests the success of immunotherapy can be predicted before treatment is administered (Photo courtesy of Weizmann Institute of Science)

Elevated Levels of Certain Immunoproteosome Components Predict Potential Success of Checkpoint Inhibitor Therapy in Melanoma Patients

Increased expression of two protein members of the “immunoproteosome” can serve as important biomarkers for stratifying melanoma patients for immune-checkpoint treatment. Checkpoint inhibitor therapy... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.